The estimated Net Worth of Shahrokh Shabahang is at least $708 Thousand dollars as of 1 June 2021. Dr Shabahang owns over 490 units of ADiTx Therapeutics stock worth over $497,888 and over the last 4 years he sold ADTX stock worth over $0. In addition, he makes $210,000 as Co-Founder, Chief Innovation Officer, and Sec. & Director at ADiTx Therapeutics.
Dr has made over 2 trades of the ADiTx Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 490 units of ADTX stock worth $1,436 on 1 June 2021.
The largest trade he's ever made was buying 602 units of ADiTx Therapeutics stock on 25 May 2021 worth over $1,499. On average, Dr trades about 156 units every 1 days since 2020. As of 1 June 2021 he still owns at least 1,016,098 units of ADiTx Therapeutics stock.
You can see the complete history of Dr Shabahang stock trades at the bottom of the page.
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. is the Co-Founder, Chief Innovation Officer, Sec. & Director at ADiTx Therapeutics.
As the Co-Founder, Chief Innovation Officer, and Sec. & Director of ADiTx Therapeutics, the total compensation of Dr D at ADiTx Therapeutics is $210,000. There are 3 executives at ADiTx Therapeutics getting paid more, with Amro Albanna having the highest compensation of $1,678,060.
Dr D is 58, he's been the Co-Founder, Chief Innovation Officer, and Sec. & Director of ADiTx Therapeutics since . There are 1 older and 11 younger executives at ADiTx Therapeutics. The oldest executive at ADiTx Therapeutics, Inc. is Dr. Joachim-Friedrich Kapp M.D., Ph.D., 79, who is the Sr. VP of Clinical Devel. - Autoimmunity.
Shahrokh's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.
Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin, and Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
ADiTx Therapeutics executives and other stock owners filed with the SEC include: